Health Care/Hospital

Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist

SHANGHAI, Sept. 14, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that it has filed investigational new drug application (IND) with US FDA for its non-alcoholic steatohepatitis (NASH) drug candidate ASC42. ASC42 is an in-...

2020-09-14 08:30 3402

Virtual reality startup and Fujitsu bring immersive drug design software to Japanese market

SAN DIEGO, Sept. 14, 2020 /PRNewswire/ -- San Diego–based virtual reality (VR) startup Nanome, Inc. has entered into an agreement with Fujitsu to bring their signature product—an immersive scientific design and collaboration platform—to the Japanese market. The software is already used by more th...

2020-09-14 08:17 3380

5 years, 500 million USD, and nearly 1,000 people: Cytiva invests for global capacity expansion

* Total planned investment is around 500 million USD over five years to raise manufacturing capacity * Continues long-term strategy of increasing capacity to respond to growing industry demand and new market opportunities * Cytiva hiring nearly 1,000 personnel in Austria, China, Singapore, S...

2020-09-14 03:00 2978

Coronavirus Breakthrough: Senhwa Reports First eIND Silmitasertib Treated Severe COVID-19 Patient - Discharged Following Five Days of Treatment

TAIPEI and SAN DIEGO, Sept. 11, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, announced today that the first patient with severe COVID-19 demonst...

2020-09-12 08:34 3409

Haoma Medica Announces Plenary Presentation for NaQuinate, a Potential Novel Treatment for Osteoporosis, at ASBMR 2020 Annual Meeting

LONDON, Sept. 12, 2020 /PRNewswire/ -- Haoma Medica announced a presentation made today at the 2020 American Society for Bone and Mineral Research: Dr Andrew Pitsillides, Professor of Skeletal Dynamics at the Royal Veterinary College, London presented 'NaQuinate: A Drug that Selectively Synergize...

2020-09-12 05:00 6133

SK Biopharmaceuticals Initiates Clinical Development Program for Cenobamate in Asia

Phase 3 clinical trial to support registrational filings in China and Japan Company on track to expand presence in Asia, reflecting its commitment to reach more people with epilepsy worldwide PANGYO, GYEONGGI PROVINCE, Korea, Sept. 12, 2020 /PRNewswire/ -- SK Biopharmaceuticals, Co., Ltd., a glo...

2020-09-12 03:13 5378

Harbour BioMed and Hualan Genetic Announced Collaboration to Develop Multiple Innovative Antibody Programs

CAMBRIDGE, Mass., ROTTERDAM, Netherlands, SUZHOU,China and XINXIANG, China, Sept. 11, 2020 /PRNewswire/ -- Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company today announced a strategic partnership agreement with Hualan Genetic Engineering Co., Ltd (Hualan Geneti...

2020-09-11 21:33 7229

NaviFUS Launches Neuronavigation-guided Clinical Trial to Open the Blood-Brain-Barrier for Combination FUS-Bevacizumab Therapy in rGBM Patients

TAIPEI, Sept. 11, 2020 /PRNewswire/ -- Genovate Biotech (TPEX:4130) subsidiary andTaiwan-based focused ultrasound (FUS) manufacturer NaviFUS Corporation is pleased to announce the start of its clinical trial (NCT04446416) for the combination of FUS plus bevacizumab therapy. Researchers at Linkou ...

2020-09-11 20:55 3638

New MAVENCLAD® Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting Highlight Rapid Onset of Action and Compelling Post-Approval Safety

In MAGNIFY-MS, patients experienced a rapid onset of action from end of Month 1 that was significant in all study periods versus baseline Post-approval safety analysis showed no increased risk of viral respiratory infections and lower rates of malignancy than in the clinical trial program Data f...

2020-09-11 20:00 5684

Booming Demand for Innodisk's CAN Bus Solutions Amid Pandemic and Autonomous Vehicle Trend

TAIPEI, Sept. 11, 2020 /PRNewswire/ -- Innodisk's CAN bus expansion modules are taking the world by storm. Unprecedented demand for autonomous vehicle technology amid the ongoing COVID-19 pandemic and continued growth of industrial automation and smart healthcare mean that Innodisk's industry-le...

2020-09-11 15:45 3755

The Air Liquide Foundation supports 10 scientific projects and 21 social emergency aid projects in the context of its Covid-19 Initiative

PARIS, Sept. 11, 2020 /PRNewswire/ -- In response to the Health crisis, the Air Liquide Foundation launched as early asMarch 2020 the Covid-19 Initiative. More than 2million euros have been mobilized over two years, with a double objective: to support scientific research projects and to reinforce...

2020-09-11 11:53 3446

Sai Life Sciences expands suite of cellular analysis platforms in Cambridge, MA

CAMBRIDGE, Mass. and HYDERABAD, India, Sept. 11, 2020 /PRNewswire/ --  Sai Life Sciences, one ofIndia's fastest growing Contract Development & Manufacturing Organizations (CDMOs) , today ann...

2020-09-11 11:30 4069

The Korea Ginseng Association, announces new direction for Korean ginseng, a publicly listed functional ingredient for bone health

SEOUL, South Korea, Sept. 11, 2020 /PRNewswire/ -- The Korea Ginseng Association announced that Korean ginseng is registered as a 'publicly listed functional ingredient for bone health" by the Ministry of Food and Drug Safety (MFDS) last July. With this news, development of various health functio...

2020-09-11 11:00 4550

Pharmalutions And Movilitas.Cloud Deliver Serialization Solutions for the Asia-Pacific Region

COLUMBIA, Md., Sept. 11, 2020 /PRNewswire/ -- Movilitas announced Pharmalutions Pte Ltd as its newest Movilitas.Cloud partner for theAsia-Pacific region. Under the partnership, Pharmalutions provides greater access to compliance-ready solutions with Movilitas.Cloud, a GAMP 5 validated software as...

2020-09-11 10:38 3233

Lionel Messi Becomes OrCam Technologies Ambassador to Advocate for Technology-Enabled Accessibility for Blind and Visually Impaired Community

Soccer giant will head global project for people who are blind or visually impaired Messi: "Witnessing each of the members of the 'Dream Team' trying out the OrCam MyEye features, it was clear that this would be a life-changing device for each of them. I am proud to be an OrCam Ambassador to tru...

2020-09-11 07:30 4967

Poor home hygiene contributing to antibiotic resistance, warn global hygiene experts

LONDON, Sept. 11, 2020 /PRNewswire/ -- It is estimated that rates of resistance to commonly-used antibiotics could exceed 40–60% in some countries by 2030.1   With antimicrobial resistance (AMR) set to claim the lives of 10 million by 2050 if no action is taken,2 the GHC's experts are calling for ...

2020-09-11 07:01 3826

Gisele Buendchen Partners With Insight Timer To Encourage Millions To Meditate For Free

Gisele Buendchen And Insight Timer Respond To The Impact Of COVID-19 On Mental Health By Leading Free Guided Meditations And Live Events On Insight Timer In English And Portuguese. NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Insight Timer, the world's largest free meditation app for anxiety, s...

2020-09-10 22:00 4503

Tottenham Acquisition I Limited Announces Filing of a Registration Statement on Form S-4 in Connection with its Proposed Business Combination with Clene Nanomedicine, Inc.

NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Tottenham Acquisition I Limited (Nasdaq: TOTA, TOTAU, TOTAW, TOTAR) ("Tottenham"), a publicly traded special purpose acquisition company, announced today that its subsidiary, Chelsea Worldwide Inc., has filed with the U.S. Securities and Exchange Commissio...

2020-09-10 20:56 21495

CMAB Biopharma and Laekna Therapeutics Enter Strategic Agreement for LAE005 Global Development and Commercialization Partnership

SUZHOU, China, Sept. 10, 2020 /PRNewswire/ -- CMAB Biopharma (Suzhou) Inc. ("CMAB"), and Laekna Therapeutics Shanghai Co., Ltd. ("Laekna Therapeutics"), today announced a strategic collaboration agreement in Suzhou BioBAY for speedup of Immune Checkpoint Inhibitor (ICI) drug candidate to the clin...

2020-09-10 20:08 1947

Merck Announces Positive Phase II Results for Investigational Sonelokinab (M1095) in Patients with Moderate to Severe Chronic Plaque-Type Psoriasis

Not intended for UK and US based media - Sonelokinab is an investigational IL-17 A/F Nanobody®, which neutralizes both IL-17A and IL-17F - Phase II study was facilitated by Avillion as part of an innovative co-development model DARMSTADT, Germany, Sept. 10, 2020 /PRNewswire/ -- Merck, a leadin...

2020-09-10 20:00 2722
1 ... 628629630631632633634 ... 808